DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rhogam (IgG Anti-D (Anti-Rh)) - Published Studies


Rhogam Related Published Studies

Well-designed clinical trials related to Rhogam (IgG Anti-D)

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. [2008.03]

Kinetics of the immune response following pneumococcal PD conjugate vaccination. [2007.03.01]

Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. [2003.01]

Well-designed clinical trials possibly related to Rhogam (IgG Anti-D)

Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. [2008.12]

A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children. [2008.08]

Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. [2008.07]

Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature. [2008.04]

Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. [2008.02]

Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. [2007.12.11]

Malaria incidence and efficacy of intermittent preventive treatment in infants (IPTi). [2007.12.09]

The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. [2007.10]

Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia: A Randomized Controlled Trial. [2007.08]

Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. [2007.05]


Prospective evaluation of high-cost management of severe chronic ITP in children and adolescents<16 years. [2006.10.15]

Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. [2006.04]

Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. [2006]

Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. [2004.12.01]

Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. [2004.04]

IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. [2004.04]

Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. [2002.03]

A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. [2001.03]

High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. [1995.07]

Multicentre trial of antepartum low-dose anti-D immunoglobulin. [1995.03]

The use of anti-D to improve post-transfusion platelet response: a randomized trial. [1995.01]

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. [1994.09.10]

Other research related to Rhogam (IgG Anti-D)

IgG-mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti-D in the prevention of haemolytic disease of the newborn? [2007.10]

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells. [2007.01]

Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. [2004.04]

Variable inhibition of placental IgG transfer in vitro with commercial IVgG preparations. [1999.12]

Evaluation by enzyme-linked immunosorbent assay of IgG anti-D and IgG subclass concentrations in immunoglobulin preparations. [1999.05]

Are there options for donor-derived i.m. anti-D IgG preparations other than to prevent Rh(D) sensitization? The intravenous route. [1995.12]

Quantification of IgG anti-D bound to D-positive red cells infused into D-negative subjects after intramuscular injection of monoclonal anti-D. [1995.06]

In vitro production of interleukin-1 receptor antagonist in IgG-mediated red cell incompatibility. [1994.04]

Cytokine production in IgG-mediated red cell incompatibility. [1993.01]

[Rhesus(D)-IgG-antibodies in the treatment of autoimmune thrombocytopenia] [1992.01.03]

[Use of anti-D (Rh) IgG or intramuscular polyvalent human immunoglobulin in the treatment of chronic autoimmune thrombocytopenic purpura] [1992]

High-dose intravenous IgG for the treatment of severe rhesus alloimmunization. [1991]

A vascular effect of IgG therapy may prevent transplacental red cell leakage and spontaneous thrombocytopenic haemorrhages. [1990.11]

Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. [1990.10]

The successful treatment of idiopathic thrombocytopenic purpura with the low dose non specific IgG component of anti D immunoglobulin. [1990]

Other possibly related research studies

The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. [2006.01]

The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration. [2005.07]

Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*. [2005.11]

[Evaluation of fetomaternal hemorrhage in postpartum patients with indication for administration of anti-D immunoglobulin] [2005.09]

Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. [2005.10]

Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. [2005.08]

Evaluation of 2-column agglutination versus conventional tube technique for antibody screening. [2003.05]

Neutropenia following IVIG therapy in pediatric patients with immune-mediated thrombocytopenia. [2005.03]

Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura. [2005.03]

[The effect of opsonins on erythrocytes' phagocytosis in the vitreous--clinical observations (Part B)] [2004]

Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin. [2004.12]

Kleihauer-betke testing is important in all cases of maternal trauma. [2004.11]

Rapid irreversible encephalopathy associated with anti-D immune globulin treatment for idiopathic thrombocytopenic purpura. [2004.11]

Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. [2004.10]

The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. [2004.09]

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. [2004.07]

Isoimmunization in pregnancy. [2004.06]

Management of immune thrombocytopenic purpura in adults. [2004.04]

After eight-year-tolerance minimal i.v. anti-D infusions unleash hemolysis in a patient with immune thrombocytopenic purpura (ITP). [2004.04]

Three cases of massive fetomaternal hemorrhage presenting without clinical suspicion. [2004.04]

Collaborative study for establishment of a global standard for the potency assay of human anti-D immunoglobulin. [2004.01]

Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. [2004.01]

Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura. [2003.11]

False positive Kleihauer tests and unnecessary administration of anti-D immunoglobulin. [2003.12]

Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. [2003.12]

A global standard for anti-D immunoglobulin: international collaborative study to evaluate a candidate preparation. [2003.11]

Rh negative status and isoimmunization update: a case-based approach to care. [2003.07]

Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. [2003.10.15]

Is the incidence of fetal-to-maternal hemorrhage increased in patients with third-trimester bleeding? [2003.06]

Prevalence of D(u) phenotype amongst rhesus negative females in Port Harcourt, Nigeria. [2003.04]

An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside. [2001.05]

Is Rh immune globulin needed in early first-trimester abortion? A review. [2003.03]

Lack of anti-D in women at birth following antepartum immune globulin prophylaxis. [2003.03.26]

Fetal-maternal hemorrhage detection in Ontario. [2003.01]

[Maternal complications of fetal hydrops] [2002.12.07]

Non-evidence-based use of Rho(D) immune globulin for threatened abortion by family practice and obstetric faculty physicians. [2002.11]

Treatment requirements of infants with rhesus isoimmunisation within a geographically defined area. [2002.11]

Perinatal immunomodulation. [2002.05]

Incidence of Rhesus isoimmunization in Rhesus-negative mothers in Ramadi, Iraq, in the mid-1990s. [2000.09]

Anti-D exerts a very early response in childhood acute idiopathic thrombocytopenic purpura. [2002.09]

Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. [2002.08]

[Foetal-maternal alloimmunizations in the South-East area of the Venice province] [2002.08]

Reported management of early-pregnancy bleeding and miscarriage by general practitioners in Victoria. [2002.01.21]

Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. [2001.10]

Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. [2002.02]

Lack of association between hepatitis C viral RNA in serum and liver and histologic gradings: a study on Irish anti-D-treated patients. [2002.03]

Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency. [2002.01]

[Immune cytopenias in newborns] [2001.09.15]

RhD isoimmunization and current management modalities. [2001.11]

Management of immune thrombocytopenic purpura in children. [2001.09]

Use of anti-D immunoglobulin in the treatment of threatened miscarriage in the accident and emergency department. [2001.11]

Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. [2001.11]

Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. [2001.06]

The frequency of anti-C + anti-G in the absence of anti-D in alloimmunized pregnancies. [2001.06]

Rhesus isoimmunization. [2001.05]

Detection of massive transplacental haemorrhage by flow cytometry. [2000.12]

Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy? [2001.05]

The first example of a paraben-dependent antibody to an Rh protein. [2001.03]

Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. [2001.01]

Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates? [2000.12]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017